Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (181-190 of 266) with videos related to

Pageof 27
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 27, 2007
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopaRobert A Hauser, Olivier Rascol, Amos D Korczyn, et al.
JAMA Neurology|November 3, 2015
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons LearnedRobert A Hauser, Fabrizio Stocchi, Olivier Rascol, et al.
Plos One|February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
CNS Spectrums|October 22, 2025
VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative reviewAmita R Patel, Robert A Hauser, Leslie Citrome, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.
Journal of Parkinson'S Disease|May 14, 2019
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal TrialsRobert A Hauser, Daniel E Kremens, Lawrence W Elmer, et al.
Clinical Pharmacokinetics|May 20, 2018
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of DyskinesiaRobert A Hauser, Rajesh Pahwa, William A Wargin, et al.
Parkinsonism & Related Disorders|August 22, 2020
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment toolRoongroj Bhidayasiri, John M Kane, Karen P Frei, et al.
Parkinsonism & Related Disorders|April 18, 2019
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's diseaseRobert A Hauser, Stuart H Isaacson, Aaron Ellenbogen, et al.
Pageof 27

Showing results (181-190 of 266) with videos related to

Sort By:
Pageof 27
Movement Disorders : Official Journal of the Movement Disorder Society|September 27, 2007
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopaRobert A Hauser, Olivier Rascol, Amos D Korczyn, et al.
JAMA Neurology|November 3, 2015
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons LearnedRobert A Hauser, Fabrizio Stocchi, Olivier Rascol, et al.
Plos One|February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
CNS Spectrums|October 22, 2025
VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative reviewAmita R Patel, Robert A Hauser, Leslie Citrome, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.
Journal of Parkinson'S Disease|May 14, 2019
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal TrialsRobert A Hauser, Daniel E Kremens, Lawrence W Elmer, et al.
Clinical Pharmacokinetics|May 20, 2018
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of DyskinesiaRobert A Hauser, Rajesh Pahwa, William A Wargin, et al.
Parkinsonism & Related Disorders|August 22, 2020
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment toolRoongroj Bhidayasiri, John M Kane, Karen P Frei, et al.
Parkinsonism & Related Disorders|April 18, 2019
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's diseaseRobert A Hauser, Stuart H Isaacson, Aaron Ellenbogen, et al.
Pageof 27